Trial Profile
A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000 [EXTENSION OF 700033856]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 17 Jan 2013 New trial record